About MyoKardia
MyoKardia is a company based in San Francisco (United States) founded in 2012 was acquired by Bristol-Myers Squibb in October 2020. MyoKardia has raised $98 million across 5 funding rounds from investors including JPMorgan Chase, Sanofi and Bristol-Myers Squibb. The company has 224 employees as of December 31, 2019. MyoKardia operates in a competitive market with competitors including Tenaya Therapeutics, Cellino, Eiger BioPharmaceuticals, Arrakis Therapeutics and Capricor Therapeutics, among others.
- Headquarter San Francisco, United States
- Employees 224 as on 31 Dec, 2019
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Myokardia Inc
-
Annual Revenue
$33.56 M (USD)193as on Dec 31, 2018
-
Net Profit
-$276.21 M (USD)-308as on Dec 31, 2019
-
EBITDA
-$287.83 M (USD)-291as on Dec 31, 2019
-
Total Equity Funding
$98 M (USD)
in 5 rounds
-
Latest Funding Round
Not available
-
Investors
JPMorgan Chase
& 5 more
-
Employee Count
224
as on Dec 31, 2019
-
Acquired by
Bristol-Myers Squibb
(Oct 05, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of MyoKardia
Unlock access to complete
Unlock access to complete
Leadership Team
394 people
Software Development Team
340 people
Senior Team
99 people
Product Management Team
97 people
Operations Team
83 people
Data Analysis and Operations Team
60 people
Sales and Marketing
58 people
Human Resources and Administration
45 people
Unlock access to complete
Funding Insights of MyoKardia
MyoKardia has successfully raised a total of $98M across 5 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in MyoKardia
MyoKardia has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include JPMorgan Chase, Sanofi and Bristol-Myers Squibb.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked | |
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Venture capital funding is provided to early-stage life science companies.
|
Locked | Locked | Locked |
Investor details for MyoKardia
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by MyoKardia
Investment portfolio details for MyoKardia
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - MyoKardia
Detailed financials for MyoKardia
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Myokardia Comparisons
Peer comparison for MyoKardia
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of MyoKardia
MyoKardia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tenaya Therapeutics, Cellino, Eiger BioPharmaceuticals, Arrakis Therapeutics and Capricor Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Regenerative and gene therapeutics for heart failure are developed.
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
|
| Locked | Locked | Locked |
Developer of antiviral agents against targets in the treatment of hepatitis
|
|
| Locked | Locked | Locked |
Provider of tools for the analysis of RNA structures
|
|
| Locked | Locked | Locked |
Regenerative medicine for cardiovascular disorders is developed using cell-based platforms.
|
Detailed competitors of MyoKardia
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Myokardia
Complete news archive for MyoKardia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MyoKardia
MyoKardia was founded in 2012.
MyoKardia is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
MyoKardia is a funded company, having raised a total of $98M across 5 funding rounds to date.
As of Dec 31, 2019, the latest employee count at MyoKardia is 224.
Annual revenue of MyoKardia is $33.56M as on Dec 31, 2018.
MyoKardia was founded in 2012 in San Francisco, United States, within the biotechnology sector. Operations center on creating therapies for cardiovascular conditions, including hypertrophic and dilated cardiomyopathy. A candidate treatment, MYK-224, targets cardiac myosin to limit excessive cross-bridge formation in hypertrophic cardiomyopathy. This mechanism seeks to control contractility, support relaxation, and lower variability in drug kinetics compared to prior options.
MyoKardia's top competitors include Esperion Therapeutics, Tenaya Therapeutics and Cellino.
MyoKardia has 6 investors. Key investors include JPMorgan Chase, Sanofi, Bristol-Myers Squibb, Perceptive Advisors, and Casdin Capital.